Life Edit Therapeutics
Nathan Wymer is a highly experienced scientist with a strong background in biochemistry and chemistry, specializing in process development for therapeutic applications. Currently serving as Principal Scientist at Life Edit Therapeutics since December 2022, Nathan focuses on downstream process development for AAV therapeutics. Prior experience includes roles as Scientist II at KBI Biopharma, where Nathan developed biomolecule purification processes, and as Assistant Professor at North Carolina Central University, delivering organic chemistry and biochemistry courses while conducting research on protein engineering. Nathan's extensive experience also includes significant contributions at Pfizer, Inc. as Principal Scientist in vaccine production technologies, and as a Scientist at zuChem, Inc., researching synthetic routes for carbohydrates. Nathan’s academic credentials include a PhD in Chemistry from Duke University and a BS in Chemistry from Purdue University, complemented by postdoctoral research at Georgia Institute of Technology.
This person is not in any offices
Life Edit Therapeutics
Life Edit, an ElevateBio company, is a next-generation genome editing company that has built a highly innovative platform with one of the world’s largest and most diverse collections of novel RNA-guided nucleases (RGNs) and base editors. The platform allows Life Edit to target any genomic sequence and develop novel human therapeutics for the most challenging genetic diseases by enabling ex vivo engineering for cell therapies and regenerative medicines and in vivo delivery of gene therapies. In addition to developing its own pipeline of cell and gene therapies, Life Edit Therapeutics will continue to strengthen its platform of genome-editing enzymes, provide gene-editing expertise to strategic partners, and form other third-party partnerships to discover and develop new therapies.